Multivariate Analysis of Factors Influencing the Clinical Study Endpoints
| Factor . | Survival5-150 . | Event-Free Survival5-150 . | Transplant-Related Mortality5-150 . | Relapse5-150 . |
|---|---|---|---|---|
| HLA-identical sibling donors valternative family donors | NS | NS | NS | NS |
| GVH-matched donors vGVH-mismatched donors | NS | NS | NS | NS |
| Early disease stage vadvanced disease stage | <0.002 | <0.001 | <0.006 | <0.04 |
| Grades 0-I acute GVHD vgrades II-IV acute GVHD | <0.0001 | <0.0001 | <0.0004 | NS |
| Patient age per decade | <0.02 | <0.01 | <0.003 | NS |
| Factor . | Survival5-150 . | Event-Free Survival5-150 . | Transplant-Related Mortality5-150 . | Relapse5-150 . |
|---|---|---|---|---|
| HLA-identical sibling donors valternative family donors | NS | NS | NS | NS |
| GVH-matched donors vGVH-mismatched donors | NS | NS | NS | NS |
| Early disease stage vadvanced disease stage | <0.002 | <0.001 | <0.006 | <0.04 |
| Grades 0-I acute GVHD vgrades II-IV acute GVHD | <0.0001 | <0.0001 | <0.0004 | NS |
| Patient age per decade | <0.02 | <0.01 | <0.003 | NS |
Significances were derived from stepwise PHGLM analysis after adjustment for explanatory variables in the models; variables not included in the table and tested not significant by univariate and multivariate analysis were HVG-matched v HVG-mismatched donor/recipient combinations, the use of G-CSF posttransplantation, GVHD-prophylactic regimen, CD34+ cell dose, donor/recipient gender combination, donor age, and underlying disease.